Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study

(2019) Jacques-Eric Gottenberg et al.   BMJ-British Medical Journal

Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma

(2019) Gaetane Nocturne et al.   RHEUMATOLOGY

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials

(2019) Renaud Felten et al.   AUTOIMMUNITY REVIEWS

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial

(2019) Iris L A Bodewes et al.   RHEUMATOLOGY

Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sjögren's syndrome

(2018) Erika P. Navarro-Mendoza et al.   AUTOIMMUNITY REVIEWS

Primary Sjögren’s Syndrome

(2018) Xavier Mariette et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome

(2018) E. William St.Clair et al.   Arthritis & Rheumatology

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome

(2018) Saba Nayar et al.   ANNALS OF THE RHEUMATIC DISEASES

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

(2017) Simon J. Bowman et al.   Arthritis & Rheumatology

Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies

(2016) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

(2016) Dinesh Khanna et al.   LANCET

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?

(2015) Valérie Devauchelle-Pensec et al.   PLoS One

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

(2014) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome

(2014) Jacques-Eric Gottenberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome

(2014) Ya-Zhuo Gong et al.   JOURNAL OF AUTOIMMUNITY

Interleukin-6 Deficiency Corrects Nephritis, Lymphocyte Abnormalities, and Secondary Sjögren's Syndrome Features in Lupus-ProneSle1.YaaMice

(2014) Jacen S. Maier-Moore et al.   Arthritis & Rheumatology

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment

(2011) K.M.A.C. Luijten et al.   AUTOIMMUNITY REVIEWS

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index

(2010) Raphaèle Seror et al.   ARTHRITIS CARE & RESEARCH

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

(2009) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

(2008) S Dass et al.   ANNALS OF THE RHEUMATIC DISEASES